Source:http://linkedlifedata.com/resource/pubmed/id/19075252
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2009-1-19
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1527-7755
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
20
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
476-7
|
pubmed:meshHeading |
pubmed-meshheading:19075252-Attitude of Health Personnel,
pubmed-meshheading:19075252-Australia,
pubmed-meshheading:19075252-Costs and Cost Analysis,
pubmed-meshheading:19075252-Medical Oncology,
pubmed-meshheading:19075252-Pharmaceutical Preparations,
pubmed-meshheading:19075252-Prescriptions,
pubmed-meshheading:19075252-United States
|
pubmed:year |
2009
|
pubmed:articleTitle |
Discussing expensive anticancer drugs.
|
pubmed:publicationType |
Letter,
Comment
|